Immunoclin (Immunoclin) Debt-to-Asset : 0.00 (As of Oct. 2014)

View and export this data going back to 2012. Start your Free Trial

What is Immunoclin Debt-to-Asset?

Immunoclin's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2014 was $0.00 Mil. Immunoclin's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Oct. 2014 was $0.00 Mil. Immunoclin's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Oct. 2014 was $20.39 Mil. Immunoclin's debt to asset for the quarter that ended in Oct. 2014 was 0.00.

Immunoclin Debt-to-Asset Historical Data

The historical data trend for Immunoclin's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunoclin Debt-to-Asset Chart

Immunoclin Annual Data

Trend

Feb12

Jan13

Jan14

Debt-to-Asset

Immunoclin Quarterly Data
	May11	Aug11	Nov11	Feb12	May12	Aug12	Nov12	Feb13	May13	Aug13	Nov13	Apr14	Jul14	Oct14
Debt-to-Asset	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Immunoclin's Debt-to-Asset

For the Biotechnology subindustry, Immunoclin's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunoclin's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunoclin's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Immunoclin's Debt-to-Asset falls into.

Immunoclin Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Immunoclin's Debt-to-Asset for the fiscal year that ended in Jan. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	21.039
	=	0.00

Immunoclin's Debt-to-Asset for the quarter that ended in Oct. 2014 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	20.391
	=	0.00

Immunoclin (GREY:IMCL) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Immunoclin Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Immunoclin's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunoclin (Immunoclin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunoclin Corp (GREY:IMCL) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

9107 Wilshire Boulevard, Suite 450, Beverly Hills, CA, USA, 90210

Website

http://www.immunoclin.com

Immunoclin Corp is engaged in immunology research and development skill to serve the pharmaceutical, biotechnology and food industries, providing comprehensive, clinical and basic science research expertise at a commercial scale and quality.

Immunoclin (Immunoclin) Headlines

No Headlines